ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2094

Evaluation of Influenza and Pneumococcal Vaccination Rate in Patients with Rheumatoid Arthritis and Spondyloarthritis, and the Attitudes of Rheumatologists About Vaccination

İdil Kurut Aysin 1, Murat Aysin 2, Dilek Solmaz 3, Nazmiye Baş Tomas 4, Filiz Koç 4, Elif Durak Ediboğlu 4, Gokhan Kabadayi 5, Onay Gercik 3, Sercan Gücenmez 4 and Servet Akar6, 1Izmir Katip Celebi University Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, 2University of Izmir Katip Celebi Faculty of Medicine, Public Health, İzmir, Turkey, 3Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, 4University of Izmir Katip Celebi Faculty of Medicine, Rheumatology, İzmir, Turkey, 5Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, 6Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, İzmir, Turkey

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Rheumatoid arthritis (RA), spondyloarthritis and rheumatologists, Vaccines

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: Infection-Related Rheumatic Disease Poster

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with inflammatory arthritis have increased risk of infections which may lead to morbidity and mortality. Some of those infections could be prevented by vaccination. The main objectives of the present study were to investigate (a) the uptake rate of influenza and pneumococcal vaccination among patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA) attending a rheumatology outpatient clinic, (b) the factors associated with their vaccination rate and, (c) the attitudes of Turkish rheumatologists about vaccination.

Methods: Patients, followed-up in a tertiary rheumatology outpatient clinic with the diagnosis of RA and SpA, volunteered for participating to study, were included in this cross-sectional study. Data regarding the socio-demographic and disease-related characteristics (including disease duration, medications used, and comorbid conditions) of the patients, vaccination history, the knowledge about the vaccination, and the factors potentially associated with the uptake of vaccination were collected by face-to-face interview using a standardized questionnaire. 102 out of 345 rheumatologists have participated in a web-based survey.

Results: In total, we collected data from 199 patients (145 with SpA and 54 with RA; 101 [50.8%] female and mean age 45.4 ± 12.2 years) (Table 1). Only 55 (27.6%) of our patients were responded that their disease or treatment might be related to the increased risk for infectious diseases. Influenza and pneumococcal vaccines were administered to 38 (19.1%) and 8 (4%) patients, respectively. Vaccination for influenza was recommended by family physicians in 16 patients and by rheumatologists in 6 patients. Rate of influenza vaccination was significantly higher in patients >65 years (p=0.031) and with any co-morbid conditions (p=0.027). The main reasons reported by unvaccinated patients were (a) the belief that they did not need the vaccine (58.4% for influenza and 30.9% for pneumococcal vaccine), (b) the absence of recommendation from their physicians (24.8% for influenza and 25.1% for pneumococcal vaccine), (c) fear of adverse event of vaccination (24.8% for influenza and 4.7% for pneumococcal vaccine), and (d) lack of knowledge vaccination (3.7% for influenza and 14.6% for pneumococcal vaccine). Even though 50% of rheumatologists who responded to the survey were aware of the presence of national vaccination recommendations, all of them stated that patients with inflammatory arthritis need to be vaccinated for both influenza and pneumococcal infections.

Conclusion: Although the knowledge and awareness about influenza and pneumococcal vaccinations were seemed to be high among rheumatologists, vaccination rates for both were insufficient in RA and SpA patients. There remains significant effort to improve vaccination rates and to prevent morbidity and mortality due to vaccine-preventable infections in inflammatory rheumatic diseases.


Disclosure: İ. Kurut Aysin, None; M. Aysin, None; D. Solmaz, None; N. Baş Tomas, None; F. Koç, None; E. Durak Ediboğlu, None; G. Kabadayi, None; O. Gercik, None; S. Gücenmez, None; S. Akar, Abbvie, 2, 5, Amgen, 2, 5, MSD, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, 8, Roche, 2, 5, UCB, 2, 5.

To cite this abstract in AMA style:

Kurut Aysin İ, Aysin M, Solmaz D, Baş Tomas N, Koç F, Durak Ediboğlu E, Kabadayi G, Gercik O, Gücenmez S, Akar S. Evaluation of Influenza and Pneumococcal Vaccination Rate in Patients with Rheumatoid Arthritis and Spondyloarthritis, and the Attitudes of Rheumatologists About Vaccination [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/evaluation-of-influenza-and-pneumococcal-vaccination-rate-in-patients-with-rheumatoid-arthritis-and-spondyloarthritis-and-the-attitudes-of-rheumatologists-about-vaccination/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-influenza-and-pneumococcal-vaccination-rate-in-patients-with-rheumatoid-arthritis-and-spondyloarthritis-and-the-attitudes-of-rheumatologists-about-vaccination/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology